Gavril Pasternak

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia
    Claire L Neilan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Brain Res 974:254-7. 2003
  2. ncbi request reprint Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy
    David A Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Neurochem 91:881-90. 2004
  3. ncbi request reprint Opiate pharmacology and relief of pain
    Gavril W Pasternak
    From Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:1655-61. 2014
  4. pmc Mu opioids and their receptors: evolution of a concept
    Gavril W Pasternak
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065
    Pharmacol Rev 65:1257-317. 2013
  5. doi request reprint Opioids and their receptors: Are we there yet?
    Gavril W Pasternak
    Molecular Pharmacology and Chemistry Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA Electronic address
    Neuropharmacology 76:198-203. 2014
  6. pmc Preclinical pharmacology and opioid combinations
    Gavril W Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 13:S4-11. 2012
  7. pmc Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1
    Jin Xu
    Department of Neurology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Pain 7:9. 2011
  8. pmc When it comes to opiates, just say NO
    Gavril W Pasternak
    Department of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:3185-7. 2007
  9. pmc Molecular insights into mu opioid pharmacology: From the clinic to the bench
    Gavril W Pasternak
    Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin J Pain 26:S3-9. 2010
  10. ncbi request reprint Incomplete cross tolerance and multiple mu opioid peptide receptors
    G W Pasternak
    Laboratory of Molecular Neuropharmacology, Dept of Neurology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New York, NY 10021, USA
    Trends Pharmacol Sci 22:67-70. 2001

Research Grants

  1. Pharmacology of opioid receptor subtype
    Gavril W Pasternak; Fiscal Year: 2010
  2. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1990
  3. Biochemical Characterization of Opioid Receptors
    Gavril Pasternak; Fiscal Year: 2007
  4. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 2002
  5. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2004
  6. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 2009
  7. Biochemical Characterization of Opioid Receptors
    Gavril W Pasternak; Fiscal Year: 2010
  8. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 1992
  9. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 2001
  10. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2003

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia
    Claire L Neilan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Brain Res 974:254-7. 2003
    ..Thus, [Dmt(1)]DALDA is a highly selective mu-opioid analgesic with significant pharmacological differences with the prototypic mu-opioid morphine...
  2. ncbi request reprint Identification of three new alternatively spliced variants of the rat mu opioid receptor gene: dissociation of affinity and efficacy
    David A Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Neurochem 91:881-90. 2004
    ..Thus, selectivity of opioid action might be achieved by designing compounds with varying efficacies at different MOR-1 variants...
  3. ncbi request reprint Opiate pharmacology and relief of pain
    Gavril W Pasternak
    From Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:1655-61. 2014
    ..Evidence suggests that these variable responses among patients have a biologic basis and are likely to involve both biased agonism and the many mu opioid receptor subtypes that have been cloned. ..
  4. pmc Mu opioids and their receptors: evolution of a concept
    Gavril W Pasternak
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065
    Pharmacol Rev 65:1257-317. 2013
    ..These chemical biologic approaches were then eclipsed by the molecular biology revolution, which now reveals a complexity of the morphine-like agents and their receptors that had not been previously appreciated. ..
  5. doi request reprint Opioids and their receptors: Are we there yet?
    Gavril W Pasternak
    Molecular Pharmacology and Chemistry Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA Electronic address
    Neuropharmacology 76:198-203. 2014
    ..This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'...
  6. pmc Preclinical pharmacology and opioid combinations
    Gavril W Pasternak
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pain Med 13:S4-11. 2012
    ..This article reviews the current state of knowledge about mu opioid receptor pharmacology, summarizes preclinical evidence for synergy from opioid combinations, and highlights the complex nature of the mu opioid receptor pharmacology...
  7. pmc Identification and characterization of seven new exon 11-associated splice variants of the rat μ opioid receptor gene, OPRM1
    Jin Xu
    Department of Neurology and Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Pain 7:9. 2011
    ..We now have examined 5' splicing in the rat...
  8. pmc When it comes to opiates, just say NO
    Gavril W Pasternak
    Department of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:3185-7. 2007
    ..This and other data suggest that peroxynitrite plays a role in opiate tolerance and that regulation of peroxynitrite may be utilized for the management of opiate-induced tolerance...
  9. pmc Molecular insights into mu opioid pharmacology: From the clinic to the bench
    Gavril W Pasternak
    Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Clin J Pain 26:S3-9. 2010
    ..Together, these sets of mu opioid receptor splice variants may help explain the clinical variability of the mu drugs among patients and provide insights into why it is so important to individualize therapy for every patient in pain...
  10. ncbi request reprint Incomplete cross tolerance and multiple mu opioid peptide receptors
    G W Pasternak
    Laboratory of Molecular Neuropharmacology, Dept of Neurology, Memorial Sloan Kettering Cancer, 1275 York Avenue, New York, NY 10021, USA
    Trends Pharmacol Sci 22:67-70. 2001
    ..Thus, incomplete cross tolerance among MOP receptor ligands might reflect their differing selectivities for these MOP receptor subtypes...
  11. ncbi request reprint Multiple opiate receptors: déjà vu all over again
    Gavril W Pasternak
    Department of Neurology, Laboratory of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Neuropharmacology 47:312-23. 2004
    ..More recent studies have now identified a number of splice variants of this clone. These splice variants may help explain the pharmacology of the mu opioids and open interesting directions for future opioid research...
  12. ncbi request reprint Mu opioid receptors in pain management
    Gavril Pasternak
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA
    Acta Anaesthesiol Taiwan 49:21-5. 2011
    ..It now appears that this gene undergoes extensive splicing, in which a single gene can generate multiple proteins. Evidence now suggests that these splice variants may help explain the clinical variability in responses among patients...
  13. ncbi request reprint Neural cell adhesion molecule and its polysialic acid moiety exhibit opposing and linked effects on neuropathic hyperalgesia
    Abderrahman El Maarouf
    Department of Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Exp Neurol 233:866-70. 2012
    ..PSA appears therefore to provide a mechanism for modulation of chronic sensory overload, by means of attenuation of the activity of the NCAM-180 isoform, which reduces nociceptive transmission...
  14. ncbi request reprint Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine
    Annie Kim Gilbert
    Laboratory of Molecular Neuropharmacology, Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Eur J Pharmacol 492:123-30. 2004
    ....
  15. pmc Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene
    Jin Xu
    Department of Neurology and The Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Neurochem 108:962-72. 2009
    ..The presence of exon 11-associated variants in humans raises questions regarding their potential role in heroin and morphine-6beta-glucuronide actions in people as they do in mice...
  16. ncbi request reprint Removal of polysialylated neural cell adhesion molecule increases morphine analgesia and interferes with tolerance in mice
    Abderrahman El Maarouf
    Department of Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Brain Res 1404:55-62. 2011
    ..In addition, the tolerance that develops with chronic morphine treatment was overcome in the absence of PSA. Interestingly, the same effects on analgesia and tolerance were also produced by selective deletion of the NCAM-180 isoform...
  17. pmc Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions
    Ying Xian Pan
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 106:4917-22. 2009
    ....
  18. ncbi request reprint Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes
    Elizabeth A Bolan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Pharmacol Exp Ther 303:557-62. 2002
    ..These findings provide further evidence for the complexity of the pharmacology of mu opioids...
  19. ncbi request reprint Identification of four novel exon 5 splice variants of the mouse mu-opioid receptor gene: functional consequences of C-terminal splicing
    Ying Xian Pan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Mol Pharmacol 68:866-75. 2005
    ..In conclusion, alterations in the amino acid sequence of the C terminus do not alter the mu-specificity of the receptor but they can influence the binding characteristics, efficacy, and potency of mu-opioids...
  20. ncbi request reprint Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X
    Ying Xian Pan
    Department of Neurology, Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Biochem Biophys Res Commun 301:1057-61. 2003
    ..These two new human mu opioid receptors are the first human MOR-1 variants containing new exons and suggest that the complex splicing present in mice may extend to humans...
  21. ncbi request reprint Analgesic synergy between topical morphine and butamben in mice
    Yuri A Kolesnikov
    Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Anesth Analg 97:1103-7, table of contents. 2003
    ..Together, these observations suggest that topical combinations of opioids and local anesthetics may prove clinically valuable...
  22. ncbi request reprint Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs
    Shayna Zelcer
    Departments of Pediatrics, Anesthesiology and Neurology, Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Brain Res 1040:151-6. 2005
    ..However, the findings also illustrate differences between the drugs within each class...
  23. ncbi request reprint Dimerization of morphine and orphanin FQ/nociceptin receptors: generation of a novel opioid receptor subtype
    Ying Xian Pan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, Weill College of Medicine of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Biochem Biophys Res Commun 297:659-63. 2002
    ..Selective kappa(1) and delta opioids did not lower binding. Despite the dramatic increase in affinity for the opioid agonists in co-expressing cells, the opioid antagonists naloxone and diprenorphine failed to compete [3H]OFQ/N binding...
  24. pmc Systemically and topically active antinociceptive neurotensin compounds
    Grace C Rossi
    Department of Psychology, C W Post Campus of Long Island University, Brookville, New York, USA
    J Pharmacol Exp Ther 334:1075-9. 2010
    ..Together, these studies support the potential of neurotensin analogs as analgesics. They are active systemically and by using them topically, it may be possible to avoid problematic side effects, such as hypothermia and hypotension...
  25. pmc Topical methadone and meperidine analgesic synergy in the mouse
    Yuri A Kolesnikov
    Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Pharmacol 638:61-4. 2010
    ..Their activity in the topical model supports their potential utility while the local limitation of their actions offers the possibility of a reduced side-effect profile...
  26. pmc Opposing actions of neuronal nitric oxide synthase isoforms in formalin-induced pain in mice
    Yuri A Kolesnikov
    Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Brain Res 1289:14-21. 2009
    ..Together, these observations illustrate the complexity of nNOS in pain perception and the existence of opposing nNOS systems likely due to splice variants of nNOS...
  27. ncbi request reprint The synergistic analgesic interactions between hydrocodone and ibuprofen
    Yuri A Kolesnikov
    Department of Anesthesiology and Critical Care, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Anesth Analg 97:1721-3. 2003
    ..Using a fixed hydrocodone:ibuprofen ratio (1:40) also revealed a marked four-fold shift to 2.6 mg/kg, SC. These findings suggest a synergistic interaction between ibuprofen and hydrocodone in a noninflammatory pain model...
  28. ncbi request reprint Codeine and 6-acetylcodeine analgesia in mice
    Steven Milo
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021, USA
    Cell Mol Neurobiol 26:1011-9. 2006
    ..5. Thus, 6-acetylcodeine is an effective mu opioid analgesic with a distinct pharmacological profile...
  29. ncbi request reprint Reorganization of dorsal root ganglion neurons following chronic sciatic nerve constriction injury: correlation with morphine and lidocaine analgesia
    Yuri Kolesnikov
    Department of Anesthesiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Eur J Pharmacol 568:124-33. 2007
    ....
  30. ncbi request reprint Sigma1 receptor modulation of opioid analgesia in the mouse
    Jianfeng Mei
    The Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, Program in Neurosciences, Cornell University Graduate School of Medical Sciences, New York, New York 10021, USA
    J Pharmacol Exp Ther 300:1070-4. 2002
    ..This enhanced response following antisense treatment was similar to that seen with haloperidol. These observations confirm the importance of sigma1 receptors as a modulatory system influencing the analgesic activity of opioid drugs...
  31. ncbi request reprint Affinity labeling mu opioid receptors with novel radioligands
    Ke Yang
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cell Mol Neurobiol 25:759-65. 2005
    ..When run on SDS-PAGE, [125I]NalAziBen binding showed a band at approximately 70-80 kDa. A control corresponding to nonspecific binding failed to reveal any labeling. No bands were observed from membranes labeled with [125I]NalAmiBen...
  32. ncbi request reprint Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm
    Elizabeth A Bolan
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Synapse 51:11-8. 2004
    ..Together, these findings reveal marked functional differences among the variants that only can be explained by their structural differences at the tip of their C-terminus...
  33. ncbi request reprint Molecular biology of opioid analgesia
    Gavril W Pasternak
    Laboratory of Molecular Neuropharmacology and Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Pain Symptom Manage 29:S2-9. 2005
    ..These multiple mu opioid receptors may help explain the range of responses seen clinically among patients for the various opioid drugs...
  34. ncbi request reprint Modulation of brainstem opiate analgesia in the rat by sigma 1 receptors: a microinjection study
    Jianfeng Mei
    The Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 1002, USA
    J Pharmacol Exp Ther 322:1278-85. 2007
    ..These studies illustrate the pharmacological importance of sigma(1) receptors in the brainstem modulation of opioid analgesia...
  35. ncbi request reprint 14-Methoxymetopon, a very potent mu-opioid receptor-selective analgesic with an unusual pharmacological profile
    Michael A King
    The Cotzias Laboratory of Neuro Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Eur J Pharmacol 459:203-9. 2003
    ..These finding demonstrate that 14-methoxymetopon is a highly potent mu-opioid with a pharmacological profile distinct from that of the traditional mu-opioid morphine...
  36. ncbi request reprint Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide
    Claire L Neilan
    Department of Neurology, 1275 York Ave, New York, NY 10021, USA
    J Pharmacol Exp Ther 306:430-6. 2003
    ..Although [3H][Dmt1]DALDA is a very potent mu-selective analgesic, its binding characteristics and its ability to stimulate GTPgammaS binding differed from that of the classical mu-opioid peptide DAMGO...
  37. ncbi request reprint Immunohistochemical labeling of the mu opioid receptor carboxy terminal splice variant mMOR-1B4 in the mouse central nervous system
    Yahong Zhang
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Brain Res 1099:33-43. 2006
    ..These studies provide evidence for the region- and neuron-specific processing of the Oprm gene and support the possibility of functional differences among the variants...
  38. pmc Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding
    Felix J Kim
    Laboratory of Molecular Neuropharmacology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Mol Pharmacol 77:695-703. 2010
    ....
  39. ncbi request reprint Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice
    Joshua F Nitsche
    Department of Neuroscience and Cell Biology, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    J Neurosci 22:10906-13. 2002
    ....
  40. ncbi request reprint Characterization of rat prepro-orphanin FQ/nociceptin((154-181)): nociceptive processing in supraspinal sites
    Grace C Rossi
    Long Island University, Brookville, New York 11548, USA
    J Pharmacol Exp Ther 300:257-64. 2002
    ..Thus, rppOFQ/N(154-181) has complex antinociceptive and pronociceptive actions within the brain, and the pharmacological specificity of its actions differs among supraspinal sites...
  41. ncbi request reprint 2,6-Dimethyltyrosine analogues of a stereodiversified ligand library: highly potent, selective, non-peptidic mu opioid receptor agonists
    Bryce A Harrison
    Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    J Med Chem 46:677-80. 2003
    ..These results illustrate the utility of acyclic, stereodiverse libraries...
  42. ncbi request reprint Dynorphin A(1-17)-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats
    Robert M Silva
    Department of Psychology and Neuropsychology Doctoral Sub Program, City University of New York, Flushing, New York 11367, USA
    J Pharmacol Exp Ther 301:513-8. 2002
    ..These converging antagonist and AS ODN data firmly implicate the kappa(1)-opioid receptor and the KOR-1 and KOR-3/ORL-1 opioid receptor genes in the mediation of dynorphin-induced feeding...
  43. ncbi request reprint Historical review: Opioid receptors
    Solomon H Snyder
    Johns Hopkins University School of Medicine, Department of Neuroscience, 725 N Wolfe Street, Baltimore, MD 21205, USA
    Trends Pharmacol Sci 24:198-205. 2003
    ..Receptor influences in binding paradigms and smooth muscle pharmacology permitted the identification and isolation of endogenous opioid peptides...
  44. ncbi request reprint The peripheral-type benzodiazepine receptor and tumorigenicity: isoquinoline binding protein (IBP) antisense knockdown in the C6 glioma cell line
    Evgeny Levin
    Rappaport Family Institute for Research in the Medical Sciences, Technion Israel Institute of Technology, Haifa, Israel
    Biochemistry 44:9924-35. 2005
    ..In conclusion, our results suggest that enhanced IBP expression, including enhanced PBR ligand binding, such as occurring in untreated C6 glioma cells, may provide a mechanism to increase apoptotic rates of cancer cells...

Research Grants62

  1. Pharmacology of opioid receptor subtype
    Gavril W Pasternak; Fiscal Year: 2010
    ..By understanding the functional roles of the various mu receptor subtypes, it may be come possible to develop analgesics lacking these side-effects, and possibly even reinforcing potential. ..
  2. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1990
    ..Additional derivatives will be examined in vivo. Finally, we will compare the metabolism and pharmacokinetics of NalBzoH following both oral and intravenous administration...
  3. Biochemical Characterization of Opioid Receptors
    Gavril Pasternak; Fiscal Year: 2007
    ..Together, these studies should give a better understanding of the actions of opioids and their pharmacology. ..
  4. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 2002
    ..Finally, we will continue our efforts to synthesize radiolabeled affinity labels. ..
  5. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2004
    ..The fourth aim will compare the binding properties of several peptide ligands for the OPRL-1 receptor. ..
  6. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 2009
    ..Together, these studies should provide insights into the role of the MOR-1 splice variants on opioid action and a better understanding of the use of these drugs. ..
  7. Biochemical Characterization of Opioid Receptors
    Gavril W Pasternak; Fiscal Year: 2010
    ..Together, these studies should give a better understanding of the actions of opioids and their pharmacology. ..
  8. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 1992
    ....
  9. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 2001
    ..Finally, we will continue our efforts to synthesize radiolabeled affinity labels. ..
  10. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2003
    ..By understanding how opioids and their modulatory systems interact, we hope to develop better approaches towards the management of pain and the discovery of new agents. ..
  11. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2005
    ..The fourth aim will compare the binding properties of several peptide ligands for the OPRL-1 receptor. ..
  12. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 1993
    ....
  13. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 2006
    ..Together, these studies should provide insights into the role of the MOR-1 splice variants on opioid action and a better understanding of the use of these drugs. ..
  14. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2001
    ..The fourth aim will compare the binding properties of several peptide ligands for the OPRL-1 receptor. ..
  15. OPIATE RECEPTOR PHARMACOLOGY
    Gavril Pasternak; Fiscal Year: 2007
    ..By examining both the receptors themselves and modulatory systems, we hope to extend our understanding of opioid analgesics and gain insights into how to use them appropriately and minimize their abuse. ..
  16. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1992
    ..Additional derivatives will be examined in vivo. Finally, we will compare the metabolism and pharmacokinetics of NalBzoH following both oral and intravenous administration...
  17. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2002
    ..The fourth aim will compare the binding properties of several peptide ligands for the OPRL-1 receptor. ..
  18. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING SITES
    Gavril Pasternak; Fiscal Year: 2003
    ..The fourth aim will compare the binding properties of several peptide ligands for the OPRL-1 receptor. ..
  19. Biochemical Characterization of Opioid Receptors
    Gavril Pasternak; Fiscal Year: 2009
    ..Together, these studies should give a better understanding of the actions of opioids and their pharmacology. ..
  20. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2007
    ..By understanding how opioids and their modulatory systems interact, we hope to develop better approaches towards the management of pain and the discovery of new agents. ..
  21. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 2007
    ..Together, these studies should provide insights into the role of the MOR-1 splice variants on opioid action and a better understanding of the use of these drugs. ..
  22. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING S
    Gavril Pasternak; Fiscal Year: 1999
    ..We also propose to explore the possibility of these splice variants and their potential role in opioid pharmacology. ..
  23. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1993
    ..Additional derivatives will be examined in vivo. Finally, we will compare the metabolism and pharmacokinetics of NalBzoH following both oral and intravenous administration...
  24. BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
    Gavril Pasternak; Fiscal Year: 1991
    ..The studies proposed in this application should further our understanding of mu and kappa receptor hetereokeneity and, hopefully, the development of highly selective anathesics lacking undesirable opioid side-effects...
  25. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2004
    ..By understanding how opioids and their modulatory systems interact, we hope to develop better approaches towards the management of pain and the discovery of new agents. ..
  26. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1999
    ..Finally, we will continue our efforts to synthesize radiolabeled affinity labels. ..
  27. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2006
    ..By understanding how opioids and their modulatory systems interact, we hope to develop better approaches towards the management of pain and the discovery of new agents. ..
  28. Synthesis and pharmacology of novel opiates and their modulatory systems
    Gavril Pasternak; Fiscal Year: 2009
    ....
  29. Biochemical Characterization of Opioid Receptors
    Gavril Pasternak; Fiscal Year: 2006
    ..Together, these studies should give a better understanding of the actions of opioids and their pharmacology. ..
  30. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 1991
    ..Additional derivatives will be examined in vivo. Finally, we will compare the metabolism and pharmacokinetics of NalBzoH following both oral and intravenous administration...
  31. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 1992
    ..Antidepressants and CCK antagonists have been used to potentiate opioid analgesia and we plan to examine these interactions with particular emphasis upon the opioid receptor subtype systems involved...
  32. BIOCHEMICAL CHARACTERIZATION OF OPIOID BINDING S
    Gavril Pasternak; Fiscal Year: 2000
    ..We also propose to explore the possibility of these splice variants and their potential role in opioid pharmacology. ..
  33. Synthesis and pharmacology of novel opiates and their modulatory systems
    Gavril W Pasternak; Fiscal Year: 2010
    ....
  34. SYNTHESIS AND PHARMACOLOGY OF NOVEL OPIATE LIGANDS
    Gavril Pasternak; Fiscal Year: 2000
    ..Finally, we will continue our efforts to synthesize radiolabeled affinity labels. ..
  35. PHARMACOLOGY OF OPIOID RECEPTOR SUBTYPES
    Gavril Pasternak; Fiscal Year: 1993
    ..Antidepressants and CCK antagonists have been used to potentiate opioid analgesia and we plan to examine these interactions with particular emphasis upon the opioid receptor subtype systems involved...
  36. Synthesis & Pharmacology of Novel Opiates and Systems
    Gavril Pasternak; Fiscal Year: 2005
    ..By understanding how opioids and their modulatory systems interact, we hope to develop better approaches towards the management of pain and the discovery of new agents. ..
  37. BIOCHEMICAL CHARACTERIZATION OF OPIATE BINDING SITES
    Gavril Pasternak; Fiscal Year: 1990
    ..The studies proposed in this application should further our understanding of mu and kappa receptor hetereokeneity and, hopefully, the development of highly selective anathesics lacking undesirable opioid side-effects...